|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300073232 |
|
最近更新日期: Date of Last Refreshed on: |
2023-07-04 17:30:28 |
|
注册时间: Date of Registration: |
2023-07-04 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于MRI的椎体骨质量评分预测经椎间孔椎体融合术后融合器沉降:一项回顾性分析 |
|
Public title: |
MRI-Based Vertebral Bone Quality Score for Predicting Cage Subsidence Following Transforaminal Lumber Interbody Fusion: A Retrospective Analysis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于MRI的椎体骨质量评分预测经椎间孔椎体融合术后融合器沉降:一项回顾性分析 |
|
Scientific title: |
MRI-Based Vertebral Bone Quality Score for Predicting Cage Subsidence Following Transforaminal Lumber Interbody Fusion: A Retrospective Analysis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
艾有为 |
研究负责人: |
刘立岷 |
|
Applicant: |
Ai Youwei |
Study leader: |
Liu limin |
|
申请注册联系人电话: Applicant telephone: |
+86 181 4665 3693 |
研究负责人电话:
Study leader's |
+86 189 8060 1394 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Aiyouwei_O@163.com |
研究负责人电子邮件: Study leader's E-mail: |
liulimin_spine@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川大学华西校区西区第二员工宿舍 |
研究负责人通讯地址: |
四川大学华西医院第一住院大楼七楼骨科六病区 |
|
Applicant address: |
The Second Staff Dormitory of West District, West China Campus, Sichuan University |
Study leader's address: |
Ward 6, Department of Orthopedics, 7th Floor, First Inpatient Building, West China Hospital, Sichuan University |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院骨科 |
||
|
Affiliation of the Leader: |
Department of Orthopedics, West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023年审(250)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Review Committee of West China Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-02-15 00:00:00 | ||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Li Na |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号老八教412-413室 |
||
|
Contact Address of the ethic committee: |
Room 412-413, Old Eight Church, No.37 Guoxue Lane, Wuhou District, Chengdu, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 3237 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
成都市国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
SCI经费卡 |
||||||||||||||||||||||
|
Source(s) of funding: |
SCI funding of hospital |
||||||||||||||||||||||
|
研究疾病: |
腰椎退行性疾病 |
||||||||||||||||||||||
|
Target disease: |
Degenerative lumbar spine disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
预后研究 |
||||||||||||||||||||||
|
Study type: |
Prognosis study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究目的以QCT为金标准,测量国人VBQ评分数据库,验证VBQ显示骨密度准确性及预测融合器沉降的效能。 |
||||||||||||||||||||||
|
Objectives of Study: |
The aim of this study was to measure the national database of VBQ scores using QCT as the gold standard to verify the accuracy of the VBQ in displaying bone mineral density and its efficacy in predicting fusion settling. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)因脊柱退行性疾病接受单节段TLIF双侧椎弓根螺钉内固定的患者,包括腰椎管狭窄、退行性腰椎滑脱、峡部裂性滑脱、腰椎间盘突出;(2)术前腰椎 CT或X线 ,非对比T1加权MRI的患者;(3)术后随访至少1年并有影像学记录的患者,包括 X 光片或 CT 扫描。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) patients undergoing a single-level TLIF with bilateral pedicle screw instrumentation for degenerative spinal conditions, including degenerative lumbar spinal stenosis, lumbar disc herniation, degenerative lumbar spondylolisthesis, and degenerative lumbar scoliosis; (2) patients with preoperative lumber CT or radiographs and non-contrast T1-weighted MRIs; (3) patients with at least 1 year of postoperative following-up with radiological imaging records including radiographs or CT scans. |
||||||||||||||||||||||
|
排除标准: |
(1)年龄<18岁;(2)患者接受过多节段TLIF,既往有脊柱融合手术史或术中明确发现终板受侵犯;(3)除骨量减少或骨质疏松外,患有Schmorl淋巴结、脊柱感染、肿瘤、外伤或代谢性骨病的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) patients with age <18 years old; (2) patients underwent multilevel TLIF, with previous spinal fusion surgery or with clearly identified endplate violation during surgery; (3) patients with Schmorls nodes, spine infection, tumor, trauma, or metabolic bone disease other than osteopenia or osteoporosis. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-02-15 00:00:00至 To 2023-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-02-15 00:00:00 至 To 2023-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
NA |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
里恩临床试验电子数据采集系统 https://www.rh-clinical.com |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Riehen Clinical Trial Electronic Data Acquisition System, https://www.rh-clinical.com |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |